Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin cancers, but presents a lower risk for respiratory malignancies.
Roughly 15% of hospitalized patients with have celiac disease (CeD) from a large cohort study had malignant neoplasms (MNs), especially small intestine, lymphoma, and skin cancers, according to results published in World Journal of Clinical Oncology.1
“The study [emphasizes] the need for vigilant screening in CeD patients, particularly for specific malignancies like small intestine, lymphoma, and skin cancers,” the authors wrote. “These findings contribute to refining CeD management and understanding broader health care trends over 2 decades.”
Using National Inpatient Sample data from roughly 53,000 hospitalized patients living with CeD in the US between 2000 and 2019, researchers found positive associations with at least 16 distinct MNs: small intestine, lymphoma, nonmelanoma skin, liver, melanoma skin, pancreas myelodysplastic syndrome, biliary, stomach, and other neuroendocrine tumors (excluding small and large intestine malignant carcinoid), leukemia, uterus, and testis.
The most significant increase was observed in cases of small intestinal adenocarcinomas, with an OR of 7.7, followed by lymphomas (OR, 2.06) and other malignancies affecting the gastrointestinal organs (OR, 2.01).
This study represents one of the largest studied cohorts of CeD, an autoimmune disorder triggered by the immune response to gluten in genetically predisposed individuals. | Image Credit: reineg-stock.adobe.com
Meanwhile, a reduced risk for respiratory and secondary malignancies was discovered. Some malignancies showed null associations with CeD, including head and neck, nervous system, esophagus, colorectal, anus, breast, malignant carcinoids, bone and connective tissues, myeloma, cervix, and ovary cancers.
Lymphomas had the highest prevalence of positive associations of malignancies with CeD. Small bowel carcinomas had the highest OR among the MNs, which showed a positive correlation with CeD, according to the study.
Mean differences in hospital stay (0.21 days) and total cost of care ($3172) were higher among the patients with CeD who also had MNs compared with patients with MNs but without CeD. But inpatient mortality was lower in CeD with MNs than non-CeD with MNs (0.72).
This study represents one of the largest studied cohorts of CeD, an autoimmune disorder triggered by the immune response to gluten in genetically predisposed individuals. The researchers used propensity score matching based on age, sex, race, and calendar year to compare patients with a primary or secondary diagnosis of CeD with patients who did not have CeD.
The CeD cohort with MN had a mean age of 68 years, 36% were male patients, and 84% reported a Caucasian race. By contrast, for the patients with CeD without MNs, the mean age was 53 years, 28% were male, and 79% reported a Caucasian race. African Americans patients comprised 1.9% of the CeD-with-MNs cohort and 2.96% of the CeD-without-MNs cohort.
The risk of MN development is higher in the early stages following a diagnosis of CeD, but the standardized incidence ratio (SIR) for MNs tends to decrease and may become statistically nonsignificant after the initial year of diagnosis or in subsequent years, the authors stated.
Worldwide, an estimated 1.4% of people have CeD based on serological markers and 0.7% based on histological data. CeD is unique because patients can halt the disease and even reverse mucosal damage by avoiding gluten.
The most common disorders associated with celiac disease are thyroid disease and type 1 diabetes, according to the Celiac Disease Foundation.2 The later the age of diagnosis, the greater the chance of developing another autoimmune disorder, with a 10.5% chance for children aged 2 to 4 years, and a 34% for those older than 20 years.
“The precise pathogenic mechanism underlying malignancy development in CeD remains an enigma. Several factors, including but not limited to persistent inflammation, the release of proinflammatory cytokines, continual antigen stimulation, cytokine surges, heightened susceptibility to carcinogens, and nutritional deficiencies induced by the disease or the adoption of a gluten-free diet, have all been proposed as potential contributors to the onset of malignancies,” the authors wrote.
References
1. Haider MB, Sbihi AA, Reddy SN, Green P. Prevalence of malignant neoplasms in celiac disease patients - a nationwide United States population-based study. World J Clin Oncol. 2024;15(8):1048-1060. doi:10.5306/wjco.v15.i8.1048
2. Autoimmune disorders. Celiac Disease Foundation. February 2013. Accessed August 31, 2024. https://celiac.org/about-celiac-disease/related-conditions/autoimmune-disorders/
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More